<DOC>
	<DOCNO>NCT01691859</DOCNO>
	<brief_summary>This multi-centre , open-label long term safety study 100 milligram ( mg ) mepolizumab administer subcutaneously ( SC ) addition standard care subject participate MEA112997 study . At clinic visit , adverse event assess exacerbation also review .</brief_summary>
	<brief_title>MEA112997 Open-label Long Term Extension Safety Study Mepolizumab Asthmatic Subjects</brief_title>
	<detailed_description />
	<criteria>Informed Consent . MEA112997 Study Participation : Received least 2 dos doubleblind investigational product MEA112997 trial . MEA112997 Treatment Assignment : If subject receive mepolizumab , must positive risk : benefit ratio . Currently treat controller medication subject controller medication past 12 week . Male Eligible Female Subjects . To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control duration trial 4 month last study drug administration . Hypersensitivity related mepolizumab . Clinically significant change health status since complete participation MEA112997 trial . A current malignancy previous history cancer remission le 12 month prior screen . For subject SAE MEA112997 assess possibly relate mepolizumab investigator . Subjects pregnant breastfeeding . Subjects enrol plan become pregnant time study participation . Screening ECG clinically significant abnormality . Received Xolair ( omalizumab ) within past 130 day . Participated clinical trial within past 30 day receive investigational medication within five terminal halflives Screen Visit , whichever longer . Current smoker .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>extension study</keyword>
	<keyword>Severe refractory asthma</keyword>
	<keyword>safety</keyword>
	<keyword>SB-240563</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>eosinophil</keyword>
</DOC>